The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation

Cancer Immunology, Immunotherapy

Volumn 58, Issue 9, 2009, Pages 1481-1488

  Tuthill, Mark ^a   Chen, Frederick ^a   Paston, Samantha ^a   De La Peña, Hugo ^a   Rusakiewicz, Sylvie ^a   Madrigal, Alejandro ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Adoptive cellular therapy; Artificial antigen presenting cells; CMV; Vaccine

Indexed keywords

ALVAC CYTOMEGALOVIRUS VACCINE; CIDOFOVIR; CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE; CYTOMEGALOVIRUS VACCINE; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; GLYCOPROTEIN B; GSK 1492903A; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PADRE CYTOMEGALOVIRUS FUSION PEPTIDE VACCINE; PHOSPHOPROTEIN 65; RECOMBINANT CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE; TOWNE VACCINE; UNCLASSIFIED DRUG; VALGANCICLOVIR; VCL CB01; VCL CB01 VACCINE; VCL CT02; VIRUS PROTEIN;

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; CD8+ T LYMPHOCYTE; CELL TRANSFER; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; EXOSOME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TREATMENT OUTCOME; VACCINATION; VIRUS REACTIVATION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 67649668430     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0722-7     Document Type: Review

References (50)

1. HJ Kolb A Schattenberg JM Goldman 1995 Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 86 2041 2050
2. A Gratwohl R Brand F Frassoni 2005 Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time Bone Marrow Transplant 36 757 769 (Pubitemid 41613298)
3. SA Fischer 2008 Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV Transplantation 86 1327 1339
4. CA Alford S Stagno RF Pass WJ Britt 1990 Congenital and perinatal cytomegalovirus infections Rev Infect Dis 12 S745 S753
5. SJ Paston IA Dodi JA Madrigal 2004 Progress made towards the development of a CMV peptide vaccine Hum Immunol 65 544 549 (Pubitemid 38686779)
6. LE Gamadia EB Remmerswaal JF Weel 2003 Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease Blood 101 2686 2692 (Pubitemid 36857631)
7. JP Casazza MR Betts DA Price 2006 Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation J Exp Med 203 2865 2877 (Pubitemid 46026164)
8. Pourgheysari B, Piper KP, McLarnon A et al (2008) Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant [Epub ahead of print]
9. MR Wills AJ Carmichael K Mynard 1996 The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL J Virol 70 7569 7579 (Pubitemid 26340108)
10. SR Riddell M Rabin AP Geballe 1991 Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression J Immunol 146 2795 2804
11. A Solache CL Morgan AI Dodi 1999 Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus J Immunol 163 5512 5518
12. F Kern IP Surel N Faulhaber 1999 Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited J Virol 73 8179 8184 (Pubitemid 29441679)
13. Z Gyulai V Endresz K Burian 2000 Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs J Infect Dis 181 1537 1546 (Pubitemid 30387742)
14. SM Stanley IA Dodi CR Evans 2006 Layer guided-acoustic plate mode biosensors for monitoring MHC-peptide interactions Analyst 131 892 894 (Pubitemid 44126545)
15. SF Lacey MC Villacres C La Rosa 2003 Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles Hum Immunol 64 440 452 (Pubitemid 36373774)
16. P Höllsberg 2002 Contribution of HLA class I allele expression to CD8+ T-cell responses against Epstein-Barr virus Scand J Immunol 55 189 195 (Pubitemid 34304558)
17. JD Altman PA Moss PJ Goulder 1996 Phenotypic analysis of antigen-specific T lymphocytes Science 274 94 96 (Pubitemid 26332731)
18. MF Callan L Tan N Annels 1998 Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo J Exp Med 187 1395 1402 (Pubitemid 28215399)
19. FE Chen G Aubert P Travers 2002 HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy Cytotherapy 4 41 48 (Pubitemid 34752390)
20. G Aubert AF Hassan-Walker JA Madrigal 2001 Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants J Infect Dis 184 955 963 (Pubitemid 32955111)
21. K Cwynarski J Ainsworth M Cobbold 2001 Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation Blood 97 1232 1240 (Pubitemid 32183744)
22. S Ganepola C Gentilini U Hilbers 2007 Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation Bone Marrow Transplant 39 293 299 (Pubitemid 46322636)
23. M Boeckh W Leisenring SR Riddell 2003 Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity Blood 101 407 414 (Pubitemid 36077556)
24. E Ozdemir RM Saliba RE Champlin 2007 Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies Bone Marrow Transplant 40 125 136 (Pubitemid 47046210)
25. G Andrei E De Clercq R Snoeck 2008 Novel inhibitors of human CMV Curr Opin Investig Drugs 9 32 45
26. B Mercorelli E Sinigalia A Loregian G Palù 2008 Human cytomegalovirus DNA replication: antiviral targets and drugs Rev Med Virol 18 177 210 (Pubitemid 351693495)
27. JM Goodrich RA Bowden L Fisher 1993 Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant Ann Intern Med 118 173 178 (Pubitemid 23034801)
28. CR Li PD Greenberg MJ Gilbert 1994 Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis Blood 83 1971 1979 (Pubitemid 24107924)
29. Schmidt-Hieber M, Schwarck S, Stroux A et al (2009) Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCT. Bone Marrow Transplant [Epub ahead of print]
30. JF Bale Jr SJ Petheram IE Souza JR Murph 1996 Cytomegalovirus reinfection in young children J Pediatr 128 347 352 (Pubitemid 26087534)
31. SH Chandler HH Handsfield JK McDougall 1987 Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted disease J Infect Dis 155 655 660 (Pubitemid 17052986)
32. SA Plotkin ML Smiley HM Friedman 1984 Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants Lancet 10 528 530 (Pubitemid 14197209)
33. RF Pass C Zhang A Evans 2009 Vaccine prevention of maternal cytomegalovirus infection NEJM 360 1191 1199
34. MK Wloch LR Smith S Boutsaboualoy 2008 Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects J Infect Dis 197 1634 1642 (Pubitemid 351919626)
35. HE Heslop MK Brenner C Rooney 1994 Administration of neomycin-resistance- gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts Hum Gene Ther 5 381 397 (Pubitemid 24310546)
36. CM Rooney CA Smith C Ng 1995 Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation Lancet 345 9 13
37. JA Madrigal PJ Travers IA Dodi 2005 Immunotherapeutic aspects of stem cell transplantation Hematology 10 Suppl 1 289 292 (Pubitemid 41825742)
38. H Dolstra F Preijers Kemenade E Van de Wiel-van 1995 Expansion of CD8+ CD57+ T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection Br J Haematol 90 300 307
39. PR Fallen RF Duarte L McGreavey 2003 Identification of non-naïve CD4+CD45RA+ T cell subsets in adult allogeneic haematopoietic cell transplant recipients Bone Marrow Transplant 32 609 616 (Pubitemid 37185097)
40. M Cobbold N Khan B Pourgheysari 2005 Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers J Exp Med 202 379 386 (Pubitemid 41126955)
41. KP Micklethwaite L Clancy U Sandher 2008 Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation Blood 112 3974 3981
42. GD Myers RA Krance H Weiss 2005 Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath) Bone Marrow Transplant 36 1001 1008 (Pubitemid 41741564)
43. Y Fujita CM Rooney HE Heslop 2008 Adoptive cellular immunotherapy for viral diseases Bone Marrow Transplant 41 193 198 (Pubitemid 351188917)
44. F André N Chaput NE Schartz 2004 Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells J Immunol 172 2126 2136 (Pubitemid 38182358)
45. E Segura S Amigorena C Thery 2005 Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses Blood Cells Mol Dis 35 89 93 (Pubitemid 41267034)
46. De La Peña H, Madrigal JA, Rusakiewicz S et al (2009) Artificial exosomes as tools for basic and clinical immunology. J Immunol Methods [Epub ahead of print]
47. M Babincová V Altanerová M Lampert 2000 Site-specific in vivo targeting of magnetoliposomes using externally applied magnetic field Z Naturforsch [C] 55 278 281 (Pubitemid 30254805)
48. JP Fortin-Ripoche MS Martina F Gazeau 2006 Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility Radiology 239 415 424
49. M Oelke MV Maus D Didiano 2003 Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells Nat Med 9 619 625
50. GA Papanicolaou JB Latouche C Tan 2003 Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele Blood 102 2498 2505 (Pubitemid 37193588)